Showing 1531-1540 of 1768 results for "".
A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.Selecting the Optimal JAK Inhibitor for Alopecia Areata
https://practicaldermatology.com/topics/hair-nails/selecting-the-optimal-jak-inhibitor-for-alopecia-areata/67265/Since 2022, the US Food and Drug Administration (FDA) has approved three oral JAK inhibitors: baricitinib, ritlecitinib, and deuruxolitinib.Looking Under the Hijab: Hair Loss and Cultural Competency
https://practicaldermatology.com/topics/hair-nails/looking-under-the-hijab-hair-loss-and-cultural-competency/67263/The rise of Muslim patients in the U.S. will require dermatologists to become more culturally aware.Best Practices for Photodynamic Therapy for Actinic Keratosis
https://practicaldermatology.com/columns/skin-cancer-essentials/best-practices-for-photodynamic-therapy-for-actinic-keratosis/67261/Photodynamic therapy (PDT) remains an effective field-directed treatment for actinic keratoses (AKs)Advancing the Science and Care of Pigmentary Disorders
https://practicaldermatology.com/topics/pigmentary-disorders/advancing-the-science-and-care-of-pigmentary-disorders/67251/These articles reflect the growing sophistication of our understanding of pathogenesis, advances in diagnostic and assessment tools, and the expanding therapeutic landscape that is reshaping patient care.The Hidradenitis Suppurativa Therapeutic Pipeline
https://practicaldermatology.com/topics/rare-disease/the-hidradenitis-suppurativa-therapeutic-pipeline/54824/Though treatment options are currently limited, the pipeline for HS therapeutics is active with numerous medications in development.Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/issues/novemberdecember-2025/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/48891/Primary hyperhidrosis (PH) is a chronic, often underreported and underdiagnosed condition without a cure. While it frequently runs in families, the exact etiology is unknown.Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/topics/rare-disease/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/39997/Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occu